1
|
Liachenko S, Ramu J, Paule MG, Hanig J. Performance of the prospective T 2 MRI biomarker of neurotoxicity in a trimethyltin model in rats at 7 T. Neurotoxicol Teratol 2023; 100:107289. [PMID: 37689269 DOI: 10.1016/j.ntt.2023.107289] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/17/2023] [Revised: 08/29/2023] [Accepted: 08/29/2023] [Indexed: 09/11/2023]
Abstract
The assessment of the sensitivity and specificity of any potential biomarker against the gold standard is an important step in the process of its qualification by regulatory authorities. Such qualification is an important step towards incorporating the biomarker into the panel of tools available for drug development. In the current study we analyzed the sensitivity and specificity of T2 MRI relaxometry to detect trimethyltin-induced neurotoxicity in rats. Seventy-five male Sprague-Dawley rats were injected with a single intraperitoneal dose of either TMT (8, 10, 11, or 12 mg/kg) or saline (2 ml/kg) and imaged with 7 T MRI before and 3, 7, 14, and 21 days after injection using a quantitative T2 mapping. Neurohistopathology (the gold standard in the case of neurotoxicity) was performed at the end of the observation and used as an outcome qualifier in receiver-operator characteristic (ROC) curve analysis of T2 changes as a predictor of neurotoxicity. TMT treatment led to a significant increase in T2 values in many brain areas. The biggest changes in T2 values were seen around the lateral ventricles, which was interpreted as ventricular dilation. The area under the ROC curve for the volume of the lateral ventricles was 0.878 with the optimal sensitivity/specificity of 0.805/0.933, respectively. T2 MRI is a promising method for generating a non-invasive biomarkers of neurotoxicity, which shows the dose-response behavior with substantial sensitivity and specificity. While its performance was strong in the TMT model, further characterization of the sensitivity and specificity of T2 MRI with other neurotoxicants is warranted.
Collapse
Affiliation(s)
- Serguei Liachenko
- Division of Neurotoxicology, NCTR, US FDA, Jefferson, AR, United States of America.
| | - Jaivijay Ramu
- Division of Neurotoxicology, NCTR, US FDA, Jefferson, AR, United States of America
| | - Merle G Paule
- Division of Neurotoxicology, NCTR, US FDA, Jefferson, AR, United States of America
| | - Joseph Hanig
- Office of Pharmaceutical Quality, CDER, US FDA, White Oak, MD, United States of America
| |
Collapse
|
2
|
The effect of crocin on apoptotic, inflammatory, BDNF, Pt, and Aβ40 indicators and neuronal density of CA1, CA2, and CA3 regions of hippocampus in the model of Alzheimer suffering rats induced with trimethyltin chloride. ACTA ACUST UNITED AC 2019. [DOI: 10.1007/s00580-019-02981-4] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022]
|
3
|
Schvartz D, González-Ruiz V, Walter N, Antinori P, Jeanneret F, Tonoli D, Boccard J, Zurich MG, Rudaz S, Monnet-Tschudi F, Sandström J, Sanchez JC. Protein pathway analysis to study development-dependent effects of acute and repeated trimethyltin (TMT) treatments in 3D rat brain cell cultures. Toxicol In Vitro 2019; 60:281-292. [PMID: 31176792 DOI: 10.1016/j.tiv.2019.05.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/14/2018] [Revised: 03/18/2019] [Accepted: 05/29/2019] [Indexed: 11/25/2022]
Abstract
Trimethyltin is an organometallic compound, described to be neurotoxic and to trigger neuroinflammation and oxidative stress. Previous studies associated TMT with the perturbation of mitochondrial function, or neurotransmission. However, the mechanisms of toxicity may differ depending on the duration of exposure and on the stage of maturation of brain cells. This study aim at elucidating whether the toxicity pathways triggered by a known neurotoxicant (TMT) differs depending on cell maturation stage or duration of exposure. To this end omics profiling of immature and differentiated 3D rat brain cell cultures exposed for 24 h or 10 days (10-d) to 0.5 and 1 μM of TMT was performed to better understand the underlying mechanisms of TMT associated toxicity. Proteomics identified 55 and 17 proteins affected by acute TMT treatment in immature and differentiated cultures respectively, while 10-day treatment altered 96 proteins in immature cultures versus 353 in differentiated. The results suggest different sensitivity to TMT depending on treatment duration and cell maturation. In accordance with known TMT mechanisms oxidative stress and neuroinflammation was observed after 10-d treatment at both maturation stages, whereas the neuroinflammatory process was more prominent in differentiated cultures than in the immature, no development-dependent difference could be detected for oxidative stress or synaptic neurodegeneration. Pathway analysis revealed that both vesicular trafficking and the synaptic machinery were strongly affected by 10-d TMT treatment in both maturation stages, as was GABAergic and glutamatergic neurotransmission. This study shows that omics approaches combined with pathway analysis constitutes an improved tool-set in elucidating toxicity mechanisms.
Collapse
Affiliation(s)
- Domitille Schvartz
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Víctor González-Ruiz
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Analytical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne, Geneva, Switzerland
| | - Nadia Walter
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland
| | - Paola Antinori
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Neuroproteomics group, Department of Clinical Neurosciences, University of Geneva, Geneva, Switzerland
| | - Fabienne Jeanneret
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Analytical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne, Geneva, Switzerland
| | - David Tonoli
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Analytical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne, Geneva, Switzerland
| | - Julien Boccard
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Analytical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne, Geneva, Switzerland
| | - Marie-Gabrielle Zurich
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Department of Physiology, University of Lausanne, Lausanne, Switzerland
| | - Serge Rudaz
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Analytical Sciences, School of Pharmaceutical Sciences, Universities of Geneva and Lausanne, Geneva, Switzerland
| | - Florianne Monnet-Tschudi
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Department of Physiology, University of Lausanne, Lausanne, Switzerland
| | - Jenny Sandström
- Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland; Department of Physiology, University of Lausanne, Lausanne, Switzerland
| | - Jean-Charles Sanchez
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, Geneva, Switzerland; Swiss Centre for Applied Human Toxicology (SCAHT), Switzerland.
| |
Collapse
|
4
|
González-Ruiz V, Schvartz D, Sandström J, Pezzatti J, Jeanneret F, Tonoli D, Boccard J, Monnet-Tschudi F, Sanchez JC, Rudaz S. An Integrative Multi-Omics Workflow to Address Multifactorial Toxicology Experiments. Metabolites 2019; 9:E79. [PMID: 31022902 PMCID: PMC6523777 DOI: 10.3390/metabo9040079] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/19/2019] [Revised: 04/03/2019] [Accepted: 04/21/2019] [Indexed: 01/02/2023] Open
Abstract
Toxicology studies can take advantage of omics approaches to better understand the phenomena underlying the phenotypic alterations induced by different types of exposure to certain toxicants. Nevertheless, in order to analyse the data generated from multifactorial omics studies, dedicated data analysis tools are needed. In this work, we propose a new workflow comprising both factor deconvolution and data integration from multiple analytical platforms. As a case study, 3D neural cell cultures were exposed to trimethyltin (TMT) and the relevance of the culture maturation state, the exposure duration, as well as the TMT concentration were simultaneously studied using a metabolomic approach combining four complementary analytical techniques (reversed-phase LC and hydrophilic interaction LC, hyphenated to mass spectrometry in positive and negative ionization modes). The ANOVA multiblock OPLS (AMOPLS) method allowed us to decompose and quantify the contribution of the different experimental factors on the outcome of the TMT exposure. Results showed that the most important contribution to the overall metabolic variability came from the maturation state and treatment duration. Even though the contribution of TMT effects represented the smallest observed modulation among the three factors, it was highly statistically significant. The MetaCore™ pathway analysis tool revealed TMT-induced alterations in biosynthetic pathways and in neuronal differentiation and signaling processes, with a predominant deleterious effect on GABAergic and glutamatergic neurons. This was confirmed by combining proteomic data, increasing the confidence on the mechanistic understanding of such a toxicant exposure.
Collapse
Affiliation(s)
- Víctor González-Ruiz
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| | - Domitille Schvartz
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, 1206 Geneva, Switzerland.
| | - Jenny Sandström
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
- Department of Physiology, University of Lausanne, 1005 Lausanne, Switzerland.
| | - Julian Pezzatti
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| | - Fabienne Jeanneret
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| | - David Tonoli
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| | - Julien Boccard
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| | - Florianne Monnet-Tschudi
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
- Department of Physiology, University of Lausanne, 1005 Lausanne, Switzerland.
| | - Jean-Charles Sanchez
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
- Translational Biomarker Group, Department of Internal Medicine Specialties, University of Geneva, 1206 Geneva, Switzerland.
| | - Serge Rudaz
- Analytical Sciences, School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1206 Geneva, Switzerland.
- Swiss Centre for Applied Human Toxicology, 4055 Basel, Switzerland.
| |
Collapse
|